Heart failure & cardiomyopathiesCohort study
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant
- Prospective cohort study
- multicentre
Cardiovascular disease (CVD) cases self-reported, centrally adjudicated by trained physicians
Authors' conclusion
Black female TTR V122I (pV142I) carriers have a higher CVD and all-cause mortality risk compared to noncarriers.
Study context
- Population
- Generally healthy postmenopausal non-Hispanic Black/African American women, Women's Health Initiative, 40 US centres, enrolled 1993–1998
- Participants
- 9,862 women
- Exposure
- The transthyretin (TTR) V122I carriers vs noncarriers
- Carriersn = 333
- Noncarriersn = 9,529reference
- Outcome
- Composite CVD (CHD, stroke, acute HF or CVD death) and all-cause mortality
- Follow-up
- Mean 16.1 years (IQR: 9.7-22.2 years)
Main finding
As reported in the abstract
Carriers
96
Incident CVD · Deaths 108
Noncarriers
2,229
Incident CVD · Deaths 2,689
Carriers vs NoncarriersHazard ratio (95% CI)
composite CVD
1.52(1.22–1.88)
all-cause mortality
1.28(1.04–1.56)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| CVD components — Carriers vs Noncarriers · acute HF | 2.21 (1.53–3.18) | |
| CVD components — Carriers vs Noncarriers · CHD | 1.80 (1.30–2.47) | |
| CVD components — Carriers vs Noncarriers · CVD death | 1.70 (1.26–2.30) | |
| 0.20.5125Hazard ratio (log scale) |
Variant frequency
- Population frequency of TTR V122I
- 3.4%
Effect modification
- Significant interaction by age; none by BP, heart rate, BMI or physical activity
Original publication
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant. JACC Heart Fail. Published 5 March 2023. doi:10.1016/j.jchf.2023.02.003
Summarised from the published abstract; every number is checked against it